Passive tumor targeting of soluble macromolecules and drug conjugates.
about
Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapyQuantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imagingDistribution of doxorubicin in rats undergoing ultrasonic drug deliveryPhase transitions of nanoemulsions using ultrasound: experimental observations.In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour.Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)An integrated approach for the rational design of nanovectors for biomedical imaging and therapy.Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer.Periodicity in tumor vasculature targeting kinetics of ligand-functionalized nanoparticles studied by dynamic contrast enhanced magnetic resonance imaging and intravital microscopyTumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies.Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery.Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis.Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing miceShort-interference RNAs: becoming medicines.A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.Intravenous magnetic nanoparticle cancer hyperthermia.Nanovehicular intracellular delivery systems.Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E(1) to promote bone formation in aged, estrogen-deficient rats.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.In vivo gene delivery by nonviral vectors: overcoming hurdles?Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses.Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticlesTumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma.Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistryImaging targeted-agent binding in vivo with two probesDiagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography.Targeted Delivery of Protein Drugs by Nanocarriers.Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.Photodynamic effect of polyethylene glycol-modified fullerene on tumor.Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
P2860
Q27015918-4A19BAC0-33E7-4A79-9F6A-65B1078329CBQ27023605-BF25237C-FEAD-4879-8094-5C128F623A33Q30404975-02997CF1-FEF2-4E95-B8E7-150CB8DAE954Q30450112-6DC29DCD-7658-4579-AFFB-E92FF62CCE2DQ33178931-D914A834-B701-4CB7-8BEA-D028FF6C17EEQ33361186-7F91E0C8-6D1A-467C-9FFB-E66C574F133EQ33679533-D5E8A95A-93C4-49BD-A3B4-34DC4B69E3E7Q33910306-AE2FB12C-83FD-4381-B1A8-8799BD197D39Q34050862-32172FE4-CB37-497B-AB4D-B5DFF3CA9B74Q34063131-420EB61B-F986-4E8E-B662-8BFA52992BEAQ34116979-04A37089-321B-4330-BF80-ED294B35C086Q34906198-5309B2C5-B106-4FDF-84DE-A6789B91847DQ35572430-54C07AAD-0E2F-44AC-959A-FA23F7F341CAQ35624010-A4017BC7-C3A8-4560-8547-5E0D92674C46Q35769042-5041183D-7E90-4085-84AB-34C2E62DABA7Q35846845-090BBD05-0458-47D4-A9AD-89F2DA0B448AQ35918821-63531F8F-8BEB-4801-B73E-D036051BC23DQ36315671-4FC41676-EA93-41D2-B8EB-0882170C13F4Q36347546-D4A9CD5C-8A9F-48B9-9129-2FFE6D5B2317Q36624086-6C97A296-0B32-4E3B-9440-3794919C30AEQ37038350-1B95ADDB-BF54-4B42-A50A-F25BA6E3FDDAQ37058812-40580705-4220-4EFA-BF73-921741AC2BB9Q37111373-E16C7A60-D16D-4BF6-AC9D-4BA89D59FD36Q37183865-2366041B-8E7D-4915-B868-AA67A4FB3708Q37307948-2920A213-18EA-4B61-BAFB-2A6932B7625FQ37689857-46C4A626-4E89-4E2E-AD56-F56569164218Q38004708-93537227-52E5-4786-9213-2DA2F9635AA7Q38107203-4157EA7E-B085-415F-B448-19808FDAC3DBQ38972263-DB2F0920-1C76-450E-B162-06C30FD9E463Q39323667-2480CB36-122F-418C-970F-5DC346290D56Q39788581-D04B0726-448D-449D-ADB2-6B7B110BCE8AQ42129363-0C8C9967-D1CF-4294-93E2-A631A5FE466DQ42286030-51021A7E-90FD-4726-8ECD-D858F3B76B00Q42582773-177EB054-7C6C-47DB-ADF8-80FE45863C04Q42706210-F1FB6E32-37D5-4D7D-9E2F-1534BA52B98AQ53075042-2C85762A-D97E-421F-ABE0-1EEB51D04463Q54647504-FB15101D-2D06-4FF3-8F6B-02E95AADF182Q55105383-19CC841F-CEBA-4A93-A737-C3575563A3B0Q55265245-5146F9F0-DD31-4701-A8B3-E09F1B10A5DEQ58758876-2A411C81-45FE-4045-809E-B8E80CDB51B6
P2860
Passive tumor targeting of soluble macromolecules and drug conjugates.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Passive tumor targeting of soluble macromolecules and drug conjugates.
@ast
Passive tumor targeting of soluble macromolecules and drug conjugates.
@en
type
label
Passive tumor targeting of soluble macromolecules and drug conjugates.
@ast
Passive tumor targeting of soluble macromolecules and drug conjugates.
@en
prefLabel
Passive tumor targeting of soluble macromolecules and drug conjugates.
@ast
Passive tumor targeting of soluble macromolecules and drug conjugates.
@en
P1476
Passive tumor targeting of soluble macromolecules and drug conjugates.
@en
P2093
Seymour LW
P304
P577
1992-01-01T00:00:00Z